Rimegepant Reduces Migraine Days: New Hope for Sufferers

Research Summary

In a recent study published in Cephalalgia, researchers examined the effectiveness and tolerability of rimegepant for preventing episodic migraines in adults who had inadequate responses to 2-4 traditional oral preventive medications. This phase 4 trial involved 652 participants, who received either rimegepant 75 mg or a placebo every other day over 12 weeks. Results showed that rimegepant significantly reduced monthly migraine days (MMDs) compared to placebo, with a mean reduction of 2.1 days. Secondary endpoints also favored rimegepant, indicating improvements in pain severity, quality of life, and migraine burden. Rimegepant's safety profile was comparable to placebo, demonstrating its efficacy and tolerability.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.